• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cortexyme Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Submission of Matters to a Vote of Security Holders

    6/10/22 5:01:03 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRTX alert in real time by email
    8-K
    false 0001662774 0001662774 2022-06-08 2022-06-08

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 8, 2022

     

     

    CORTEXYME, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-38890   90-1024039

    (State or other jurisdiction of

    incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    269 East Grand Ave.

    South San Francisco, California

      94080
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (415) 910-5717

    Not Applicable

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.001 per share   CRTX   Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    ITEM 1.01 Entry into a Material Definitive Agreement.

    On June 8, 2022, Cortexyme, Inc. (the “Company”) entered into a Sublease Agreement (the “Sublease”) with ICON Clinical Research, LLC, effective as of May 5, 2022, pursuant to which the Company leases certain premises located at 601 Gateway Boulevard in South San Francisco, California (the “Premises”). The term of the Sublease commences on June 18, 2022 (“Commencement Date”) and extends to November 30, 2023, unless sooner terminated in accordance with the terms of the Sublease (the “Initial Term”). The Company has certain option to extend the Initial Term for additional one month until December 31, 2023 (the “Optional Extension Term”). The base rent for the Premises from the 11th day after the Commencement Date to the 12th calendar month and from the 13th calendar month to the end of the Initial Term will be $16,692 and $17,205.60 per month, respectively. The base rent for the Premises during the Optional Extension Term will be $17,205.60 per month.

    The foregoing description of the terms of the Sublease is not complete and is qualified in its entirety by reference to the complete texts of the Sublease, a copy of which will be filed with the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2022.

    ITEM 2.03 Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant.

    The disclosure included in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 by reference.

    ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Departure of Executive Officer and Director

    On June 8, 2022, Christopher Lowe, the Chief Financial Officer, Chief Operating Officer and a member of the Board of Directors (the “Board”) of the Company, resigned as a member of the Board, effective immediately. Mr. Lowe has also resigned from his roles as the Chief Financial Officer and Chief Operating Officer of the Company, effective as of June 10, 2022 (the “Departure Date”). In connection with the departure of Mr. Lowe from the Company, the Company entered into a separation agreement (the “Separation Agreement”) with Mr. Lowe on June 10, 2022, providing for (i) a release of claims against the Company; (ii) cash severance payments of $354,750, which equals to nine months of Mr. Lowe’s 2022 base salary, to be paid in accordance with the Company’s normal payroll practices; and (iii) certain health care continuation benefits. The Separation Agreement also provides for an accelerated vesting of the restricted stock award issued to Mr. Lowe on March 3, 2022 and an extension of the post-termination exercise period for all vested stock options or other equity awards held by Mr. Lowe through the twelve-month period following the Departure Date, provided that the specified severance preconditions are met. In addition, in the event the Company consummates a change in control within three months after the Departure Date, subject to satisfaction of specified conditions, Mr. Lowe would also be entitled to additional cash severance and COBRA coverage, payment of target annual bonus and accelerated vesting with respect to his equity awards.

    The foregoing description of the terms of the Separation Agreement is not complete and is qualified in its entirety by reference to the complete texts of the Separation Agreement, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2022.

    Mr. Lowe’s resignation from the Board was not a result of any disagreement with the Company, its Board or management.


    Appointment of Director

    On June 9, 2022, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed June Bray to serve as a Class III director of the Company, effective immediately, to fill the vacant directorship, until her successor is elected and qualified, or sooner in the event of her death, resignation or removal. Ms. Bray joins the class of directors whose term expires at the Company’s 2025 annual stockholders’ meeting.

    Ms. Bray is entitled to receive compensation in accordance with the Company’s Outside Director Compensation Policy as currently in effect (the “Policy”).

    In accordance with the Policy, Ms. Bray is entitled to receive a $38,000 annual retainer for service as a Board member.

    On the effective date of her appointment, Ms. Bray was granted an initial stock option award under the Company’s 2019 Equity Incentive Plan covering 54,000 shares of the Company’s common stock pursuant to the Policy, delivered in the form of a nonstatutory stock option. The exercise price of the options will equal $3.20, the closing sales price of the Company’s common stock on the date of grant, and the options will vest in equal annual installments over the three-year period following the date of grant, subject to the director’s continued service as a director through each such vesting date.

    The Company has entered into the Company’s standard form of indemnification agreement with Ms. Bray. The indemnification agreement provides, among other things, that the Company will indemnify Ms. Bray for certain expenses which she may be required to pay in connection with certain claims to which she may be made a party by reason of her position as a director of the Company, and otherwise to the fullest extent permitted by law. The form of indemnification agreement was previously filed as Exhibit 10.2 to the Company’s Registration Statement on Form S-1 (No. 333-230853), as amended, as originally filed on April 12, 2019, and is incorporated herein by reference.

    There are no arrangements or understandings between Ms. Bray and any other persons pursuant to which she was selected as a member of the Board. There are no family relationships between Ms. Bray and any director, executive officer, or any person nominated or chosen by the Company to become a director. Ms. Bray is not a party to any current or proposed transaction with the Company for which disclosure is required under Item 404(a) of Regulation S-K.

    Designation of Principal Financial Officer

    On June 9, 2022, the Company designated Ted Monohon, the Company’s Chief Accounting Officer and Vice President of Finance, as the principal financial officer, to fill the vacancy resulting from Mr. Lowe’s resignation from the Company. Mr. Monohon will serve as the principal financial officer in addition to his role as a principal accounting officer.

    Mr. Monohon, 56, has served as the Company’s Chief Accounting Officer and principal accounting officer since February 2021 and as the Vice President of Finance since May 2019. Prior to joining the Company, Mr. Monohon was a Consultant at SOA Projects, Inc. from December 2018 to April 2019, and he served as Head of Accounting and Finance at X10 Capital Management, LLC from March 2017 to December 2018. Mr. Monohon has more than 20 years of financial experience spanning roles at private equity, publicly and privately held companies and major banks. Mr. Monohon’s expertise includes key finance functions including financial planning and forecasting, treasury and cash management, and accounting and tax functions. During his career, Mr. Monohon has completed multiple initial public offerings as well as venture capital and private placement financings. He began his career with Deloitte as a senior staff auditor. Mr. Monohon obtained his bachelor’s degree in Accounting from the Rochester Institute of Technology.


    The Company has entered into the Company’s standard form of indemnification agreement with Mr. Monohon. The indemnification agreement provides, among other things, that the Company will indemnify Mr. Monohon for certain expenses which he may be required to pay in connection with certain claims to which he may be made a party by reason of his position as an officer of the Company, and otherwise to the fullest extent permitted by law. The form of indemnification agreement was previously filed as Exhibit 10.2 to the Company’s Registration Statement on Form S-1 (No. 333-230853), as amended, as originally filed on April 12, 2019, and is incorporated herein by reference.

    There are no arrangements or understandings between Mr. Monohon and any other persons pursuant to which he was designated as the Company’s principal financial officer. There are no family relationships between Mr. Monohon and any director, executive officer, or any person nominated or chosen by the Company to become a principal financial officer of the Company. Mr. Monohon is not a party to any current or proposed transaction with the Company for which disclosure is required under Item 404(a) of Regulation S-K. In connection with his designation as the principal financial officer, there will not be any change in compensation or benefits of Mr. Monohon.

    ITEM 5.07 Submission of Matters to a Vote of Security Holders.

    The Annual Meeting of Stockholders of the Company was held online via live audio webcast on June 8, 2022 (the “Annual Meeting”). At the Annual Meeting, there were present, in person virtually or by proxy, holders of 20,722,574 shares of common stock, or approximately 68.7% of the total outstanding shares eligible to be voted. The final voting results with respect to each proposal presented at the Annual Meeting is set forth below:

    Proposal One - Election of Directors

    The Company’s stockholders approved the election of two Class III directors to the Board for three year terms or until their respective successors are elected and qualified or until their earlier death, resignation or removal. The results of such vote were:

     

    Nominee

     

    Votes For

     

    Votes Withheld

     

    Broker Non-Votes

    Christopher Lowe

      12,537,677   659,522   7,525,375

    Christopher J. Senner

      12,563,414   633,785   7,525,375

    Proposal Two - Ratification of Selection of Independent Registered Accounting Firm

    The Company’s stockholders ratified the selection of BDO USA, LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2022. The results of such vote were:

     

    Votes For

     

    Votes Against

     

    Abstentions

    20,441,558

      80,308   200,708


    Proposal Three - Approval, on an advisory basis, of the compensation of the Company’s named executive officers

    The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The results of such vote were:

     

    Votes For

     

    Votes Against

     

    Abstentions

     

    Broker Non-Votes

    10,710,462

      2,437,368   49,369   7,525,375


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CORTEXYME, INC.
      By:  

    /s/ Caryn G. McDowell

    Date: June 10, 2022   Name:   Caryn G. McDowell
      Title:   Chief Legal and Administrative Officer and Corporate Secretary
    Get the next $CRTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRTX

    DatePrice TargetRatingAnalyst
    3/9/2022$30.00 → $15.00Buy
    HC Wainwright & Co.
    1/28/2022$75.00 → $12.00Buy → Hold
    Canaccord Genuity
    1/28/2022Buy → Hold
    Canaccord Genuity
    1/27/2022Mkt Outperform → Mkt Perform
    JMP Securities
    10/27/2021Neutral → Underperform
    B of A Securities
    10/27/2021$58.00 → $15.00Neutral → Underperform
    BofA Securities
    10/27/2021$200.00 → $30.00Buy
    HC Wainwright & Co.
    9/16/2021$75.00 → $150.00Buy
    Canaccord Genuity
    More analyst ratings

    $CRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022

    New ticker symbol (NASDAQ:QNCX) to initiate trading on August 1, 2022 Cortexyme, Inc. (NASDAQ:CRTX) today announced that the company's planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the corporate name change, the company plans to issue a news release that will provide a business update detailing Quince Therapeutics' go-forward growth strategy and development pipeline plans. Additionally, the company's ticker symbol on the Nasdaq Global Select Market is expected change to "QNCX" effective at the open of market trading on Monday, August 1, 2022. The company's common stock will continue to trade under the ticker sym

    7/27/22 8:01:00 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

    Once daily dose of COR588 over 10-day period well-tolerated with no serious adverse events observed Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful completion of its Phase 1 single ascending dose and multiple ascending dose (SAD/MAD) clinical trial of COR588, the company's lysine gingipain inhibitor in development for the treatment of Alzheimer's disease and indications with disease pathology associated with the keystone pathogen P. gingivalis. The study was a randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerability, an

    7/27/22 8:00:00 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

    Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company's 3CLpro inhibitor, COR803, for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection. In ongoing preclinical research, COR803 successfully reduced viral load of SARS-CoV-2 in vivo after oral treatment. COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition. 3CLpro, or Mpro, is a validated antiviral drug target shown to be essential in viral r

    6/21/22 8:00:00 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRTX
    Financials

    Live finance-specific insights

    View All

    Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer's Disease Progression

    In overall population, co-primary endpoints of ADAS-Cog11 and ADCS-ADL were not met Pre-specified subgroups representing up to half of the participants based on P. gingivalis infection level showed approximately 50% slowing of cognitive decline Clinical data validated upstream mechanism of action and benefits of targeting P. gingivalis Additional top-line GAIN Trial results to be presented at CTAD 2021 on November 11th Cortexyme to host investor conference call today Tuesday, October 26th at 4:30 p.m. Eastern Time Cortexyme, Inc. (NASDAQ:CRTX) today reported top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat

    10/26/21 4:01:00 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Monohon Ted covered exercise/tax liability with 1,640 shares, decreasing direct ownership by 5% to 29,311 units to cover taxes

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    12/7/22 5:37:47 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4: Monohon Ted covered exercise/tax liability with 1,520 shares, decreasing direct ownership by 5% to 30,951 units to cover taxes

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    9/8/22 5:58:12 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Monohon Ted

    4 - Cortexyme, Inc. (0001662774) (Issuer)

    7/1/22 5:03:16 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Cortexyme with a new price target

    HC Wainwright & Co. reiterated coverage of Cortexyme with a rating of Buy and set a new price target of $15.00 from $30.00 previously

    3/9/22 6:45:17 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Cortexyme from Buy to Hold and set a new price target of $12.00 from $75.00 previously

    1/28/22 7:19:09 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme downgraded by Canaccord Genuity

    Canaccord Genuity downgraded Cortexyme from Buy to Hold

    1/28/22 6:06:43 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRTX
    SEC Filings

    View All

    Cortexyme Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

    12/16/22 4:04:17 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Cortexyme Inc.

    10-Q - Quince Therapeutics, Inc. (0001662774) (Filer)

    11/9/22 4:17:03 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme Inc. filed SEC Form 8-K: Leadership Update

    8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

    9/30/22 5:08:03 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cortexyme Inc. (Amendment)

    SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)

    7/8/22 12:56:11 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Cortexyme Inc. (Amendment)

    SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)

    2/11/22 2:48:42 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Cortexyme Inc. (Amendment)

    SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)

    2/11/22 12:22:48 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRTX
    Leadership Updates

    Live Leadership Updates

    View All

    Cortexyme Appoints June Bray to its Board of Directors

    Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company's Board of Directors. "We are very pleased to welcome a seasoned pharmaceutical and global regulatory expert of June Bray's caliber to our Board of Directors," said David Lamond, chairperson of Cortexyme's Board of Directors. "With more than four decades of pharmaceutical industry experience, we look forward to her valuable contribution and perspective across multiple therapeutic areas." "I am excited to join Cortexyme's B

    6/13/22 8:00:00 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme Appoints Dr. Philip Low to Its Board of Directors

    Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S. Low, a renowned targeted drug discovery researcher and veteran biotech entrepreneur, to the company's Board of Directors. "In conjunction with today's acquisition of Novosteo, we are very pleased to welcome a distinguished researcher, innovator, and entrepreneur of Dr. Philip Low's caliber to our Board of Directors," said David Lamond, chairman of Cortexyme's Board of Directors. "His vast expertise across targeted drug discovery, prolific research abilities, and pro

    5/20/22 8:01:00 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme Announces Agreement to Acquire Novosteo

    Expanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury Strengthening leadership team with appointment of Novosteo executives Dr. Dirk Thye as CEO and Dr. Karen Smith as CMO of combined company Planning corporate name change to Quince Therapeutics to reflect broadening of therapeutic pipeline Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases, today announced that it entered into an agreement under which the company plans to acquire Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skelet

    5/10/22 8:00:00 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care